At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 165 enrolled
Drug / intervention
Galcanezumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (Galcanezumab) in Patients With Episodic or Chronic Cluster Headache
In Brief
A Phase 3 clinical trial evaluating Galcanezumab for Episodic Cluster Headache and Chronic Cluster Headache. Completed, enrolled 165 participants across 40 sites in 12 countries.
Detailed Summary
The main purpose of this study is to assess the long-term safety and tolerability of galcanezumab administered up to once monthly in participants with episodic or chronic cluster headache who have completed study I5Q-MC-CGAL (NCT02397473) or study I5Q-MC-CGAM (NCT02438826).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartJul 2016
Primary CompletionJan 2021
TodayJul 2026
First PostedJun 14, 2016
Enrollment StartJul 13, 2016
Primary CompletionJan 21, 2021
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 10.0 years ago
Interventions
Galcanezumabdrug
Administered SC